Evidence map›Paper›PMID 35166183›Full record

ArticleJournal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology2022

Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study.

Malak El Sabeh, Kathleen L Vincent, Sadia Afrin, Massoud Motamedi, Jamal Saada, Jinping Yang, Bulent Ozpolat, Gokhan S Kilic, Mostafa A Borahay

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Simvastatin-loaded liposomal nanoparticles as treatment for adenomyosis in a patient-derived xenograft mouse model: a pilot study.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. The Role of Nanomedicine in Benign Gynecologic Disorders.Molecules (Basel, Switzerland) · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Malak El SabehDepartment of Gynecology & Obstetrics, Johns Hopkins University, Baltimore, MD, USA.
Kathleen L VincentDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA.
Sadia AfrinDepartment of Gynecology & Obstetrics, Johns Hopkins University, Baltimore, MD, USA.
Massoud MotamediDepartment of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA.
Jamal SaadaDepartment of Anesthesiology, University of Texas Medical Branch, Galveston, TX, USA.
Jinping YangDepartment of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA.
Bulent OzpolatDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gokhan S KilicDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA.
Mostafa A BorahayDepartment of Gynecology & Obstetrics, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-0554-132X
The University of Texas Medical Branch at Galveston · USJohns Hopkins University · USThe University of Texas MD Anderson Cancer Center · US

Funding

Role of senescent cells in uterine fibroid pathogenesisR01HD111243 · JOHNS HOPKINS UNIVERSITY · 2025 to 2025
$792k
NCATS NIH HHS UL1 TR000071NICHD NIH HHS R01 HD094380NICHD NIH HHS R01 HD111243
6 · The paper itself

Abstract

Uterine leiomyomas are complex tumours with limited medical treatment options. Simvastatin is used to treat hypercholesterolaemia and has shown promising effects as a treatment option for leiomyomas. Previously, our group demonstrated a promising effect of simvastatin treatment in a patient-derived xenograft mouse model. Here, we tested the efficacy of simvastatin liposomal nanoparticles (NPs). After bilateral leiomyoma xenograft implantation, mice (N = 12) were divided into three treatment arms: control, simvastatin and simvastatin-loaded liposome NPs (simvastatin-NPs). Treatment with simvastatin significantly reduced tumour volume and inhibited the Ki67 expression when compared to the control group. There was a trend of reduced tumour volume and Ki67 expression after treatment with simvastatin-NP; however, the results were not significant. Due to low bioavailability and short half-life of simvastatin, liposomal NPs have the potential to enhance drug delivery, however, in this study NP did not provide improvement over simvastatin, but did demonstrate their potential for the delivery of simvastatin.Impact statement

Indexed as

LeiomyomaNanoparticlesAnimalsDisease Models, AnimalHeterograftsHumansKi-67 AntigenLiposomesMicePilot ProjectsSimvastatinKi-67 AntigenLiposomesSimvastatinanimal modelfibroidnanoparticlessimvastatinUterine leiomyoma

Identifiers

PMID35166183
PMCPMC9741872
OpenAlexW4213195014

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.